Research ExplorerPublicationsTherapie des metastasierten Prostatakarzinoms im Wandel – ne...

Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen

Standard

Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen. / Albers, P; Bögemann, M; Machtens, S; Merseburger, A S; Schostak, M; Steuber, T; Wülfing, C; De Santis, M.

In: UROLOGE, Vol. 59, No. 3, 03.2020, p. 307-317.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Albers, P, Bögemann, M, Machtens, S, Merseburger, AS, Schostak, M, Steuber, T, Wülfing, C & De Santis, M 2020, 'Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen', UROLOGE, vol. 59, no. 3, pp. 307-317. https://doi.org/10.1007/s00120-019-01072-0

APA

Albers, P., Bögemann, M., Machtens, S., Merseburger, A. S., Schostak, M., Steuber, T., Wülfing, C., & De Santis, M. (2020). Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen. UROLOGE, 59(3), 307-317. https://doi.org/10.1007/s00120-019-01072-0

Vancouver

Albers P, Bögemann M, Machtens S, Merseburger AS, Schostak M, Steuber T et al. Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen. UROLOGE. 2020 Mar;59(3):307-317. https://doi.org/10.1007/s00120-019-01072-0

Bibtex

@article{47ae844a755b4822b5e9800997d47d07,
title = "Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen",
abstract = "The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients with metastatic prostate cancer and may also result in longer patient survival. The therapeutic sequence of ARTAs and taxanes may influence outcome and therefore decisions should be made on an individual basis. This article provides guidance for therapeutic decision-making in daily clinical practice by working out criteria that can be used to support individual therapeutic decisions. The focus is on metastatic castration-naive prostate cancer, oligometastatic disease as well as non-metastatic and metastatic castration-resistant prostate cancer.",
keywords = "Androgen Antagonists, Antineoplastic Agents, Hormonal/therapeutic use, Hormone Replacement Therapy, Humans, Male, Molecular Targeted Therapy, Prostate-Specific Antigen/blood, Prostatectomy/methods, Prostatic Neoplasms, Castration-Resistant/blood, Treatment Outcome",
author = "P Albers and M B{\"o}gemann and S Machtens and Merseburger, {A S} and M Schostak and T Steuber and C W{\"u}lfing and {De Santis}, M",
year = "2020",
month = mar,
doi = "10.1007/s00120-019-01072-0",
language = "Deutsch",
volume = "59",
pages = "307--317",
journal = "UROLOGE",
issn = "0340-2592",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen

AU - Albers, P

AU - Bögemann, M

AU - Machtens, S

AU - Merseburger, A S

AU - Schostak, M

AU - Steuber, T

AU - Wülfing, C

AU - De Santis, M

PY - 2020/3

Y1 - 2020/3

N2 - The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients with metastatic prostate cancer and may also result in longer patient survival. The therapeutic sequence of ARTAs and taxanes may influence outcome and therefore decisions should be made on an individual basis. This article provides guidance for therapeutic decision-making in daily clinical practice by working out criteria that can be used to support individual therapeutic decisions. The focus is on metastatic castration-naive prostate cancer, oligometastatic disease as well as non-metastatic and metastatic castration-resistant prostate cancer.

AB - The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients with metastatic prostate cancer and may also result in longer patient survival. The therapeutic sequence of ARTAs and taxanes may influence outcome and therefore decisions should be made on an individual basis. This article provides guidance for therapeutic decision-making in daily clinical practice by working out criteria that can be used to support individual therapeutic decisions. The focus is on metastatic castration-naive prostate cancer, oligometastatic disease as well as non-metastatic and metastatic castration-resistant prostate cancer.

KW - Androgen Antagonists

KW - Antineoplastic Agents, Hormonal/therapeutic use

KW - Hormone Replacement Therapy

KW - Humans

KW - Male

KW - Molecular Targeted Therapy

KW - Prostate-Specific Antigen/blood

KW - Prostatectomy/methods

KW - Prostatic Neoplasms, Castration-Resistant/blood

KW - Treatment Outcome

U2 - 10.1007/s00120-019-01072-0

DO - 10.1007/s00120-019-01072-0

M3 - SCORING: Zeitschriftenaufsatz

C2 - 31781782

VL - 59

SP - 307

EP - 317

JO - UROLOGE

JF - UROLOGE

SN - 0340-2592

IS - 3

ER -